333PRibociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018) - Cardoso, F; Papazisis, K; De Laurentiis, M; Ring, A; Lu, J; Martín, M; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Zarate, J P; Cottu, P H